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in Melanoma
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Soogyeong Ha1, Hee Jung Kim3, Jung Min Park4, Tae Sung Kim5, Wang Jae Lee6, Byung Joo Cho7,
Sa Ik Bang8, Hyunjeong Park3,9 and Daeho Cho1,9
Erythroid differentiation regulator (Erdr1) was first discovered in mouse leukemia cell lines and functions as a
stress-related survival factor. This study investigated whether Erdr1 regulates murine melanoma progression, as
well as the mechanism involved in Erdr1-regulated metastasis. The expression of Erdr1 is negatively correlated
with IL-18 expression, which has a pro-cancer effect in melanoma. To study the role of Erdr1 as an anti-cancer
factor, cell migration, invasion, and proliferation were measured. Erdr1 overexpression markedly inhibited
the level of cell migration, invasion, and proliferation in B16F10 cells in vitro. In addition, Erdr1 overexpression
significantly suppressed melanoma lung colonization, metastasis, and tumor growth in vivo. To identify the
factors involved in Erdr1-reduced metastasis, heat shock protein 90 (HSP90), a well-known stress protein
and contributor to tumor metastasis, was examined. We found that HSP90 was significantly decreased in
Erdr1-overexpressing cells. Functional analysis demonstrated that HSP90 small-interfering RNA transfection
reduced the migration ability and metastasis of melanoma. In conclusion, Erdr1 shows a powerful anti-
metastasis effect that leads to the ability to reduce the metastatic potential of murine malignant melanoma cells.
Erdr1 is an anti-metastatic factor that may be a possible therapeutic target for treatment of melanoma.
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INTRODUCTION
Melanoma is one of the most malignant skin tumors and
has high mortality and metastatic characteristics (Mancianti
and Herlyn, 1989). Despite improved understanding of
melanoma pathophysiology, current immunological therapeu-
tic approaches are still insufficient (Chin, 2003). Metastasis
occurs through a multistep process through which cancer
cells spread to distant sites to promote secondary colonies
and to induce cancer-related mortality. Cell motility, includ-
ing migration and invasion, has an important role in
metastasis (Boyd, 1996). Various factors affect the migration
and invasion of melanoma, such as growth factors, chemo-
kines, and cytokines (Bouzahzah et al., 2001; Versteeg et al.,
2004; Miyata et al., 2006).
IL-18 is an 18-kDa cytokine that belongs to the IL-1
cytokine superfamily. It is known to be an IFN-g-inducing
factor and is a well-known proinflammatory cytokine
(Okamura et al., 1995; Zhang et al., 1997; Golab, 2000).
IL-18 induces both anti-cancer and pro-cancer factors and
therefore has dual effects on cancer metastasis (Park et al.,
2007). It is produced by various immune and non-immune
cells (Stoll et al., 1997; Kampfer et al., 2000), and it has been
reported that murine melanoma cell lines secrete IL-18,
and endogenous IL-18 is associated with immune escape
of murine melanoma cells by autocrine action patterns
(Huber et al., 1992; Ferrone and Marincola, 1995; Mukherji
and Chakraborty, 1995). IL-18 is also known to induce
melanoma motility, and a previous study has demonstrated
that IL-18 treatment enhanced the migration ability of B16F10
murine melanoma cells (Jung et al., 2006). This implies a
positive correlation between enhanced IL-18 expression and
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malignant skin cancers, including melanoma, suggesting
important roles of IL-18 in the malignancy of skin tumors.
In addition, IL-18 production level is elevated by various
stressors that are required for IL-18 maturation and secretion.
Several studies have suggested that stressors enhance
melanoma progression and induce escape from the host
immune surveillance system (Temoshok, 1985; Antoni et al.,
2006). It is also reported that psychological stress-related
hormones and various physical stressors such as reactive
oxygen species and UV irradiation markedly promote mela-
noma metastasis (Satyamoorthy and Herlyn, 2002; Hyoudou
et al., 2008).
Recently, it was demonstrated that erythroid differentia-
tion regulator 1 (Erdr1) is released from cells under stress
conditions (Dormer et al., 2004b). Erdr1 was first detected in
mouse leukemia cell lines and has since been found to be
expressed in many different normal murine tissues (Dormer
et al., 2004b). Erdr1 has hemoglobin synthesis-inducing
properties and can suppress the survival of Burkitt’s
lymphoma cell line BL-70 by maintaining homeostasis of
cell growth (Dormer et al., 2004a).
Although both IL-18 and Erdr1 are known as stress-related
factors, the relationship between IL-18 and Erdr1 has not
been elucidated until now. Furthermore, no information
is available about the effect of Erdr1 on the regulation
of the cancer metastatic process and related mechanisms,
especially in melanoma. This study suggests that Erdr1
inhibits cell migration and invasion and suppresses meta-
static potential of murine melanoma cells by regulation of
HSP90 expression.
RESULTS
Erdr1 is expressed in normal skin cells but not melanoma
To compare the expression levels of Erdr1 between normal
skin cell and melanoma cell lines, we investigated Erdr1
expression levels in various skin cells involving normal
human melanocytes, keratinocytes, dermal fibroblasts, and
various human melanoma cell lines, such as SK-MEL-2,
SK-MEL-5, and murine melanoma cells line, B16F10. Our
preliminary study suggested that the human Erdr1 sequence
derived by human tissue cDNA showed 100% homology
with murine sequence (data not shown). Interestingly, as
shown Figure 1a, only normal human primary keratinocytes
and melanocytes expressed Erdr1. To further confirm this
finding, immunohistochemistry was performed on samples
obtained from normal and melanoma patients. The results
showed that Erdr1 is distributed only in the normal epidermis,
which mainly includes keratinocytes, Langerhans cells, and
melanocytes but not in melanoma patients (Figure 1b),
indicating that Erdr1 may have key functions in melanoma
as common features between humans and mouse.
Erdr1 is negatively regulated by IL-18 in melanoma
In previous studies, it has been suggested that IL-18
modulates the immune escape of murine melanoma cells
by controlling the level of Fas ligand and regions of interest
(ROIs). B16F10/IL-18 antisense transfectants have been
established to express a lower level of IL-18 by transfection
with IL-18 antisense cDNA (Cho et al., 2000). In this study,
B16F10/IL-18 antisense transfectants were used to determine
whether Erdr1 is regulated by IL-18 in the melanoma cell
line B16F10. The expression level of Erdr1 was determined
using reverse transcriptase-PCR (RT-PCR) and western blot.
Figure 2 shows that the level of Erdr1 was significantly
increased in B16F10/IL-18 antisense transfectants compared
with B16F10 wild-type controls. This suggests that Erdr1 is
negatively regulated by IL-18 expression. As IL-18 has been
reported to have pro-cancer effects, we next investigated
whether Erdr1 could act as an anti-cancer factor (Carrascal
et al., 2003; Gaggero et al., 2004; Majima et al., 2006).
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Figure 1. Erdr1 is expressed in the normal skin but not melanoma. (a) Erdr1 western blot of human skin cells and melanoma cell lines. Normal keratinocytes
and melanocytes expressed Erdr1 protein but not human and melanoma cells; lane 1: 10 human keratinocyte, lane 2: 10 human melanocyte, lane 3: 10 human
fibroblast, lane 4: SK-MEL-2 (human melanoma cell line), lane 5: SK-MEL-5 (human melanoma cell line), lane 6: B16F10 (murine melanoma cell line),
lane 7: Erdr1-overexpressed B16F10 cells used as positive control. Representative data of three independently performed experiments are shown.
(b) Comparison of Erdr1 expression between normal and melanoma patients. Erdr1 staining is shown as brown-red colors (*: Erdr1 staining region). Erdr1
expression was observed only in normal epidermal layers but not in melanoma patients. Bar¼25 mm. Magnification  200. Isotype indicated that normal
rabbit IgG was used as a negative control. Representative data of 5 normal and 30 melanoma patients are shown. Erdr1, erythroid differentiation regulator.
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Overexpression of Erdr1 reduced cell migration, invasion, and
proliferation
To evaluate the effect of Erdr1 in the murine melanoma cell
line B16F10, B16F10 cells were transiently transfected with
murine Erdr1 cDNA and used for subsequent studies. RT-PCR
and western blot analysis with a specific antibody against
Erdr1 revealed that Erdr1-transfected cells highly expressed
Erdr1 (Figure 3a).
Cell motility, such as invasion and migration ability, is a
key initial step in the tumor metastatic process. To determine
whether Erdr1 regulates the migration ability of melanoma
cells, a transwell migration assay was performed. Figure 3b
(left) shows that the migration ability of the group over-
expressing Erdr1 was B40% lower than that of the vector
transfection group. To determine the possible role of Erdr1 in
the invasiveness of melanoma cells, a Matrigel-coated
transwell was used for invasion assay. As shown in Figure
3b (right), invasion ability was significantly suppressed by
B50% following Erdr1 overexpression.
Erdr1
Erdr1
B16F10
B16F10/
asIL-18
B16F10
B16F10/
asIL-18
β-Actin
α-Tubulin
Figure 2. Erdr1 is negatively regulated by IL-18 in melanoma. Comparison of
Erdr1 expression between B16F10 and B16F10 antisense IL-18 (asIL-18)
murine melanoma cell lines. (a) Total RNA was extracted from each set of
cells. RNA was reverse transcribed, and PCR was performed after reverse
transcription with primers for Erdr1 or b-actin. PCR products were analyzed
by 1.5% agarose gel electrophoresis. (b) Western blot of B16F10 cells and
B16F10 antisense IL-18 to detect Erdr1. Antisense IL-18 B16F10 cells
expressed a higher amount of Erdr1 protein than the empty vector transfected
group. Representative data of three independently performed experiments are
shown. Erdr1, erythroid differentiation regulator.
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Figure 3. Erdr1 overexpression inhibited melanoma migration invasion and proliferation. (a) B16F10 cells were transfected with Erdr1 cDNA using
Lipofectamine. RT-PCR analysis was performed to determine Erdr1 mRNA expression. Total RNA was isolated from cells, and reverse transcription was
performed, followed by PCR with oligonucleotides specific for Erdr1 or b-actin (left). Erdr1 western blot of B16F10 cells transfected with indicated
plasmids. Erdr1 plasmid-transfected cells expressed a higher amount of Erdr1 protein than did empty vector-transfected cells (right). g-Tubulin was used in equal
amounts as loading control. (b) Cells transfected with empty vector or Erdr1 plasmid were placed in the migration chamber and allowed to migrate for 12 hours.
Migration ability was decreased in Erdr1-transefected cells (left). Erdr1- or empty vector-transfected cells were added to Matrigel-coated wells for 24 hours.
Invaded cells were stained with crystal violet staining solution and assessed by microscope observation. Erdr1-transfected cells displayed an inhibitory pattern of
cell invasion (right). Bar¼ 100mm. These data are representative of three independent experiments. Vector, empty vector transfectants; Erdr1, Erdr1 plasmid
transfectants. (c) Erdr1- or empty vector-transfected cells were allowed to proliferate in 96-well plates for 6, 24, 48, 72, or 96 h. Proliferated cells were analyzed
by CyQUANT assay. Erdr1-transfected cells inhibited melanoma proliferation. RFU, relative fluorescence units. The data are reported as mean±SD. *Po0.05,
Vector versus Erdr1-transfected groups. (d) B16F10 cells were proliferated with 0, 1, 10, or 100 ngml1 recombinant Erdr1 for 72 hours. Proliferation was
suppressed in a dose-dependent manner. The data are reported as mean±SD. *Po0.05, control versus rErdr1 treatment groups. (e) B16F10 cells were
overexpressed with Erdr1 and subjected to 2D-gel analysis (top). The differently expression spots were analyzed by MASCOT program. The table shows
Erdr1-regulated cell motility-regulated molecules determined by MALDI-TOF (bottom). The data are reported as mean±SD. *Po0.05 level, and which
have been analyzed using MALDI-TOF mass spectrometry (Vector vs. Erdr1-transfected group). Erdr1, erythroid differentiation regulator; MALDI-TOF, matrix-
assisted laser desorption ionization-time of flight; RT-PCR, reverse transcriptase-PCR; 2D, two dimensional.
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Next, we investigated the effect of Erdr1 on melanoma
proliferation. As expected, proliferation of cells overexpres-
sing Erdr1 wa markedly lower than for vector transfection
control cells (Figure 3c). The suppressive effect of Erdr1 on
cell proliferation was further confirmed by exogenous
treatment with 0, 1, 10, and 100ngml1 of recombinant
Erdr1 for 72 hours. The proliferation efficiency of Erdr1 was
reduced in a dose-dependent manner (Figure 3d). These data
suggest that Erdr1 inhibits not only the migration and invasive
capacity of B16F10 cells but also suppresses proliferation,
indicating that Erdr1 acts as a potent suppressor of melanoma
motility.
To find molecules related to Erdr1 regulation, proteomic
analysis was performed. B16F10 cells transfected with Erdr1
cDNA or with an empty vector are subjected to analysis
in two-dimensional gels. The differentially expressed distinct
spot was analyzed by matrix-assisted laser desorption ioniza-
tion-time of flight, and several adhesion molecules that were
identified show evidence that Erdr1 may regulate some
molecules including vimentin, serpina, tropomyosin, and
N-cadherin (Figure 3e). These molecules have been reported
to regulate cancer migration and invasion (Jeanes et al., 2008;
Quarta et al., 2010; Lees et al., 2011; Vuoriluoto et al., 2011).
In particular, N-cadherin is a well-known cell adhesion
molecule documented as a pro-invasion factor in melanoma
(Haass et al., 2005). This suggests that Erdr1-mediated
melanoma motility and proliferation maybe regulated by
adhesion molecules.
Melanoma cells overexpressing Erdr1 inhibit HSP90 expression
Next, the regulatory factor by which Erdr1 is able to regulate
cell motility was investigated. As referred in the ‘‘Introduc-
tion’’ section, IL-18 and Erdr1 are closely associated with
stress. Thus, we tried to find the factor regulated by Erdr1
and showed anti-cancer effect, related to stress condition.
Heat shock protein (HSP) has been reported as a pro-cancer
factor, and it can induce active invasion ability of cancer cells
(Soo et al., 2008). In particular, HSP90 is reported to be
enhanced in advanced malignancy melanoma, and its
inhibitor displays anticancer effects (Becker et al., 2004;
Eccles et al., 2008; McCarthy et al., 2008; Tsutsumi et al.,
2008). Figures 4a and b show a decrease in HSP90 mRNA
and protein in the group overexpressing Erdr1.
To further confirm that Erdr1-reduced cell migration is
mediated directly by HSP90, a migration assay with HSP90
small-interfering RNA (siRNA)-transfected cells was per-
formed. As expected, the migration ability of the HSP90
siRNA-transfected group was B35% lower than that of the
control group (Figure 4d). On the basis of these results, it was
concluded that Erdr1 inhibits expression of HSP90 and that
this is the mechanism by which Erdr1 suppresses motility of
melanoma cells. This indicates that Erdr1-inhibited melano-
ma migration occurs by downregulation of HSP90.
Erdr1 overexpression suppressed tumor metastasis and induced
prolonged survival
We next examined whether Erdr1 affects melanoma meta-
stasis in vivo using C57/BL6 syngenic mice. Melanoma cells
transfected with Erdr1 cDNA or with an empty vector were
injected intravenously into the tail vein of mice, and the
number of lung metastases was counted. As shown in Figure
5a, lung colonization was significantly inhibited in the
Erdr1-transfected group. In addition, cells were subcuta-
neously implanted into mice, and the tumor growth and
survival rate were investigated. The Erdr1-overexpressed
group showed reduction of tumor growth and prolonged
survival rate (Figure 5b and c). To further confirm that
Erdr1-reduced metastasis is also mediated by HSP90 in vivo,
HSP90 siRNA-transfected cells were injected into mice. As
expected, the group injected with HSP90 siRNA-transfected
cells showed lower metastatic density (Figure 5d). These
in vivo data indicate that Erdr1 effectively suppressed
metastatic ability of melanoma through downregulation of
HSP90 and may therefore be an anti-cancer factor, which to
our knowledge is previously unreported.
DISCUSSION
In this study, the relationship between IL-18 and Erdr1 in
melanoma has been studied and suggests the effect of Erdr1
on melanoma metastasis. Many reports have recently shown
that elevated expression of IL-18 has pro-cancer effects, such
as inducing cell migration and immune escape of melanoma
cells (Cho et al., 2000; Jung et al., 2006). Despite the
apparent pro-cancer effects of IL-18, more study is required to
better understand other related factors and its specific
mechanism in melanoma.
Here, we show that Erdr1 is primarily expressed in normal
melanocytes but not in melanoma cell lines, and the tissue
staining of normal and melanoma patients showed that only
the normal epidermis expressed Erdr1 and not the normal
dermis or samples from melanoma patients (Figure 1). It is
well known that the major cells present in the epidermis are
keratinocytes, Langerhans cells, Merkel cells, and melano-
cytes. These cells have the possibility to be closely associated
with Erdr1. In addition, we have suggested that Erdr1 is
regulated by IL-18 in melanoma cells. As it is reported that the
production of IL-18 and Erdr1 is affected by stress (Sugama
et al., 2000; Tong et al., 2008), we hypothesized that IL-18
and Erdr1 may be associated. Interestingly, results in this study
indicate that murine melanoma cells, B16F10 with down-
regulated IL-18, had increased Erdr1 expression (Figure 2).
This indicates that the IL-18 expression level is negatively
correlated with the expression of the stress-related factor,
Erdr1. Taken together, our data show that Erdr1 may have a
critical role in melanoma progression as an anti-cancer factor.
In dissecting the role of Erdr1 in melanoma progression
in vitro, we found that overexpression of Erdr1 inhibits
melanoma cell migration and invasion (Figure 3b). Cell
motility such as invasion and migration ability is a key step in
the tumor metastatic process. In addition to these in vitro
findings, the current study also showed that Erdr1 over-
expression dramatically inhibited melanoma lung metastasis
and induced prolonged survival in vivo (Figure 5a and b). The
proliferation ability of melanoma cells was also suppressed
by Erdr1 overexpression in vitro and in vivo (Figures 3c
and 5c). In addition to the anti-cancer effect of Erdr1 seen by
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overexpression, we also investigated the effects of exogenous
treatment with recombinant Erdr1. The proliferation ability
of B16F10 cells was reduced after treatment with recombi-
nant Erdr1 in a dose-dependent manner (Figure 3d), indicating
that the Erdr1 recombinant protein can also act as an
anti-cancer factor. On the basis of these results, it can be
concluded that the anti-metastatic role of Erdr1 contributes,
at least in part, to the inhibition of invasive properties and
extravasation capacity of melanoma cells and suppressing of
proliferation.
In this study, we show that Erdr1 is negatively regulated by
IL-18, a well-known member of the IL-1 cytokine family, and
inhibits melanoma metastasis in vitro and in vivo, indicating
that is has a crucial function as an anti-cancer factor, which
to our knowledge is previously unreported. Taken together,
various genes regulated by IL-1 family cytokine may have
vital roles in modulating tumor metastasis.
Next, the regulatory factor by which Erdr1 is able to
regulate cell motility was investigated. HSP is a well-known
representative stress-related protein, and its expression is
increased when elevated heat stress or other stress is present
(Sarto et al., 2000). HSP90 is found in numerous cancer
cells including melanoma cells, and its expression is
positively correlated with metastatic potential (Becker et al.,
2004; Whitesell and Lindquist, 2005; McCarthy et al., 2008).
Recently, small-molecule HSP90 inhibitors such as geldana-
mycin and its derivatives have been evaluated for their
anticancer activity (Zhang et al., 2004; Dai and Whitesell,
2005). Demethoxygeldanamycin-N-oxide, a cell-imperme-
able HSP90 inhibitor, which to our knowledge is previously
unreported, has been shown to suppress melanoma motility
through actin reorganization and redistribution of focal
adhesion kinase in melanoma cells and acts as a key factor
for enhancement of survival rate (Tsutsumi et al., 2008). This
shows that inhibition of HSP90 expression or activity induces
anti-tumor effects and prolonged survival. On the basis of
these reports, it can be hypothesized that HSP90 is a possible
regulatory factor in Erdr1-suppressed tumorigenesis. This
study found that overexpression of Erdr1 leads to down-
regulation of HSP90 (Figure 4a and b). In addition, siRNA
of HSP90-transfected melanoma cells inhibited melanoma
migration ability in vitro and suppressed metastasis in vivo
(Figure 4d and 5d). Accordingly, this implies that Erdr1-
suppressed melanoma metastasis is induced by inhibition of
HSP90 activity.
The mechanism underlying how Erdr1 regulates HSP90
is not yet known. Matrix-assisted laser desorption ionization-
time of flight analysis revealed the possibility that Erdr1 may
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regulate some adhesion molecules, including N-cadherin,
which is a well-known pro-invasion factor (Haass et al.,
2005; Jeanes et al., 2008) (Figure 3e). Fanelli et al. (2008)
suggested that P-cadherin interacts with HSP to induce
metastasis of breast cancer. According to this, cadherins
may have the ability to regulate Erdr1 and its regulated
mechanism with HSP90. In our preliminary data, ROI level
was reduced by Erdr1 (data not shown). ROI caused oxidative
stress and contributes to various cancer processes, including
migration and invasion (McCord, 2002; Jung et al., 2006).
Oxidative stress-induced stimulation of HSP90 was also
reported (Liu et al., 2007). Therefore, we hypothesized that
reduced ROI by Erdr1 leads to suppression of HSP. In
addition, it was documented that IL-18 regulated coronary
artery smooth muscle cell migration by regulating matrix
metalloproteinase-9 (Chandrasekar et al., 2006). In breast
cancer, HSP90 interaction with matrix metalloproteinase-2
and matrix metalloproteinase-9 enhances cancer metastasis
(Stellas et al., 2010). Here, we found that Erdr1 is regulated
by IL-18 and suppressed HSP90 expression (Figures 2 and 4).
Therefore, matrix metalloproteinase-9 has the ability to act as
a representative protease related to Erdr1-regulated HSP90
activity. Overall, some cadherins, ROI, and proteases may
participate in Erdr1-related activities associated with HSP90
regulation. Additional study is required to determine the
specific molecules associated with the role of Erdr1 in
melanoma metastasis.
In conclusion, Erdr1 suppressed metastasis in the murine
melanoma cell line, B16F10, through downregulation of
HSP90 expression. This study found that Erdr1 is negatively
regulated by IL-18, and its overexpression resulted in
inhibited melanoma metastasis in vitro and in vivo. It implies
that Erdr1 overproduction inhibits tumor progression. Taken
together, our investigation provides the first evidence that
Erdr1 has an important role as an anti-metastasis factor,
which to our knowledge is previously unreported, through
inhibition of HSP90, suggesting an effective therapeutic target
for melanoma.
MATERIALS AND METHODS
Cell culture
B16F10 (murine melanoma cell line), SK-MEL-2, and SK-MEL-5
(human melanoma cell line) cells were cultured in DMEM
supplemented with 2mM L-glutamine, 100Unitsml1 penicillin,
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100mgml1 streptomycin, and 10% heat-inactivated fetal bovine
serum. Human primary keratinocytes, melanocytes, and fibroblast
cells were purchased as commercially and cultured in recommended
growth media (Cascade Biologics, Portland, OR). Cells were cultured
at 37 1C in a humidified atmosphere containing 5% CO2. Cells were
used for experiments while they were in the log phase of growth.
Construction of Erdr1 cDNA
For construction of mouse Erdr1 expression vector, the complete
coding sequence of Erdr1 was isolated by PCR amplification from
B16F10 cell cDNA using primers based on the known sequences
(Genbank Accession No: AJ_539223). The Erdr1 cDNA fragments
were digested with EcoR I and Xho I and ligated into pcDNA3.1(þ )
(Invitrogen, Carlsbad, CA). Plasmid DNA used for transfection was
prepared using an endo-free plasmid Maxi kit (Qiagen, Valencia,
CA). For each plasmid, the A260/A280 was determined spectro-
photometrically and was typically between 1.8 and 2.0. Absence of
RNA and genomic DNA was confirmed by gel electrophoresis.
Transient transfection of cells
Cells were cultured in an antibiotic-free medium and reached 90 to
95% confluence. Cells were transfected with plasmid containing the
full-length murine Erdr1 cDNA or empty vector, pcDNA3.1(þ ), and
HSP90 siRNA (Santa Cruz, Delaware, CA) using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s recommendation.
Transfection was confirmed by RT-PCR and western blot before
functional studies.
Recombinant protein
The Erdr1-pCMV-SPORT6 plasmid was purchased from Open
Biosystems (Open Biosystems, Huntsville, AL). The coding sequence
region of Erdr1 was transferred into a bacterial expression vector
system. The 177 amino-acid Erdr1 protein was expressed in
Escherichia coli systems and purified from the soluble fraction
of bacterial lysate. Purified protein was dialyzed into phosphate-
buffered saline (PBS). The purity of protein was determined by SDS-
PAGE (495%), and endotoxin level of protein was measured using
the LAL system (Cape Code, East Falmouth, MA) (o0.1 EUml1).
RT-PCR
Total RNA was extracted from B16F10 melanoma cells using
TRIzol (Invitrogen) according to the instructions of the manufacturer.
After reverse transcription, cDNA was incubated with the follow-
ing primers: (1) Erdr1, sense 50-CAGTGATGTCACCCACGAAA-30,
antisense 50-GGCATTTCTGTACGCAGTCA-30 (2) HSP90, sense
50-TCGGCACCATAGCCAAATCT-30, antisense 50-AACCGACACCA
AACTGGCCA-30 (3) b-actin, sense 50-TCACCCACACTGTGCCCAT
CTACG-30, antisense 50-CAGCGGAACCGCTCATTGCCAATG-30,
for PCR amplification. The cycling conditions were: over 25 cycles
of denaturing (94 1C, 30 seconds), annealing (55 1C, 30 seconds), and
extension (72 1C, 30 seconds), with a final extension at 72 1C for
10minutes.
Western blot analysis
Polyclonal anti-Erd1 antibody was generated in rabbits using a
C-terminal Erdr1 peptide of 36–51 amino acids (C-RAPRPPRHTR
HTRHTR-NH2) for immunization according to standard protocols.
Cells were washed twice with ice-cold PBS, and protein
was extracted in ice-cold lysis buffer (50mM Tris-HCl (pH 7.4), 1%
NP-40, 0.25% deoxycholic acid sodium salt, 150mM NaCl, 1mM
EDTA, and a protein inhibitor cocktail). After collecting the cell
lysate, protein quantity was determined using a Bradford assay
(Bio-Rad, Hercules, CA). An equal volume of protein from each
sample was separated by 12% SDS-PAGE under reducing conditions
and transferred to a polyvinylidene difluoride membrane (Bio-Rad).
The membrane was blocked with 5% non-fat dried milk for 1 hour
and then incubated with Erdr1 antibodies, HSP90 antibodies (Santa
Cruz), or tubulin antibodies (Cell Signaling Technology, Danvers,
MA) overnight. After washing, the membrane was incubated for
1 hour with either goat anti-rabbit IgG antibody or donkey anti-goat
IgG antibody conjugated with biotin and then incubated for
30minutes with horseradish peroxidase (Amersham Pharmacia
Biotech, Buckinghamshire, UK). Each of the proteins was detected
using an Amersham ECL system (Amersham Pharmacia Biotech).
Immunohistochemistry
The study was approved by the ethics committee of the Catholic
University of Korea and all patients filed informed consents. The
study was conducted according to the Declaration of Helsinki
principles. In all, 5 normal and 30 melanoma patient samples
were collected. Formalin-fixed, paraffin-embedded tissue sections
were deparaffinized and rehydrated in a graded series of alcohol.
Anti-Erdr1 was used as the primary antibody at a 1:1,000 dilution
and incubated on slides in a wet chamber overnight at 41C. Antigen
was detected using a streptavidin–biotin–peroxidase detection system
(Cap-plus Detection kit; Invitrogen, Camarillo, CA) with 3-amino-
9-ethylcarbazole as the chromogen. Normal rabbit IgG was used as
a negative control.
Migration and invasion assay
Migration assay was performed using a Transwell chamber (Costar,
Cambridge, MA) with 8-mm pore polycarbonate filters. In brief,
before migration and invasion assay, cells were treated with
mitomycin C (25 mgml1) for 1 hour. Next, harvested cells were
suspended in 100ml serum-free media at a final concentration
of 5 104 cells per ml and added to upper chambers. The medium
containing 10% fetal bovine serum was placed in the lower
chamber. After incubation for 12 hours, cells that migrated through
the pores of the membrane were stained with a staining solution
(0.1% crystal violet in ethanol) and dissolved in 10% acetic acid.
The O.D. values at 570 nm were measured using an ELISA reader
(Molecular Devices, Sunnyvale, CA). Invasion assay was performed
using Matrigel invasion chambers (Becton Dickinson, Sunnyvale,
CA) pre-coated with Matrigel matrix. Cells were introduced into
upper chambers in 100 ml serum-free media at a final concentration
of 1 105 cells per ml, and medium containing 10% fetal bovine
serum was added to the lower compartment. After invasion for
24 hours, analysis of invasion ability was performed using the same
methods as the migration assay.
Proliferation assay
Cell proliferation assay was performed using a CyQUANT cell
proliferation kit (Molecular Probes, Camarillo, CA). B16F10 cells
(5 103/200ml) were seeded on a 96-well plate and incubated in
a humidified incubator at 37 1C with 5% CO2 for 6, 24, 48, 72, or
96 hours. At the indicated time point, culture media were removed
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from each of the wells and cells were incubated at 80 1C for
30minutes. Cells were then thawed at room temperature for DNA
fragmentation. In all, 200ml CyQUANT green fluorescent dye
in cell-lysis buffer was then added to each well to identify cellular
nucleic acids. Samples were incubated at room temperature for
5minutes and protected from light. Fluorescence was measured
using a Fluorescence microplate reader (Molecular Devices) at
485 nm excitation and 530nm emission.
Proteomics analysis
B16F10 cells transected with Erdr1 cDNA or with an empty
vector were extracted in ice-cold lysis buffer (50mM Tris-HCl (pH
7.4), 1% NP-40, 0.25%, 150mM sodium chloride, 1mM EDTA,
10mM sodium fluoride, 1mM sodium vanatate, 1mM phenylmethyl-
sulfonyl fluoride, 10 mgml1 aprotinin, and 10 mgml1 leupeptin)
and subjected to analysis in two-dimensional gels. For the first
dimension, isoelectric focusing was performed overnight on 13-cm,
immobilized, pH 4–7 linear gradient strips. The second-dimensional
separation was performed on 12% acrylamide separating gel.
After running, the gel was stained by Coomassie brilliant blue
staining method and the spots were visualized. The differentially
expressed distinct spots were excised and performed for in-gel
trypsin digestion under optimal conditions. They were subjected to
matrix-assisted laser desorption ionization-time of flight analysis.
The proteins were identified using MASCOT algorithm (Matrix
Science, Boston, MA).
Flow-cytometry analysis
Intracellular FACS analysis was performed to detect HSP90 in
melanoma cell lines. In brief, cells were washed in PBS containing
0.05% BSA and 0.02% sodium azide. After two washes, cells were
fixed in 2% paraformaldehyde in PBS for 15minutes on ice.
Thereafter, cells were washed once in cold PBS-BSA and resus-
pended in PBS containing 0.1% saponin and 0.05% sodium azide
(permeabilization buffer) for 15minutes, followed by incubation
with rabbit anti-mouse HSP90 antibody (Santa Cruz) for 30minutes
on ice. After two washes, cells were further incubated with an
appropriate FITC-conjugated secondary antibody in permeabiliza-
tion buffer for 30minutes on ice, followed by three washes. A
FACScan (Becton Dickinson) flow cytometer was used for analysis.
In vivo tumorigenicity model
Six-week-old C57BL/6 mice were purchased from SLC (Haruno,
Japan) and maintained for 1 week before beginning experiments. To
examine the metastatic potential of B16F10 cells, mice were
inoculated intravenously with cells (5 104 cells/100 ml PBS)
transfected with or without Erdr1 cDNA, HSP90 siRNA (n¼ 8).
Two weeks after inoculation, mice were killed and lungs were
excised for counting the number of colonies. For examination
of tumor growth and survival rate, Erdr1- or vector-transfected
B16F10 cells (1 105 cells/200 ml PBS) were subcutaneously
injected into C57BL/6 mice. Thereafter, tumor size was determined
by caliper measurement every 2 days. The survival rate of each
group (n¼ 10) was also measured. Experiments were performed as
three independent experiments. All animal experiments were
approved by Industry Academic Cooperation Foundation, Sookmyung
Women’s University (Approval no. SMU-IACUC-2008-0902-001),
and all experiments followed the regulatory standards.
Statistics
Statistical analysis was performed using an unpaired Student’s t-test.
P-values of o0.05 were considered statistically significant.
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